CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1)

• Before Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously with replacement therapy. (2.1)
• After Extraction: Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days. Infuse no more than 1 mL/minute to avoid hypotension. (2.1).
• Reduce the dosage for patients with renal impairment. (2.2, 8.6)

• Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose ampules (3)
• Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose vials (3)

• In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. (4)
• In patients with active intravascular clotting. (4)
• In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. (4)

• Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. (5.1)
• Risk of Medication Errors Due to Incorrect Route of Administration: FOR INTRAVENOUS USE ONLY. (5.2)
• Seizures: Inadvertent injection into neuraxial system may result in seizures. (5.3)
• Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. (5.4)
• Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. (5.5)
• Dizziness: Advise patients not to drive if dizziness occurs. (5.6)

Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. (5.1, 7.1, 8.3)